Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine



Summary

This research explores combining oncolytic viruses and p53-enhanced dendritic cell (DC) vaccines to improve cancer immunotherapy. Specifically, DCs were genetically modified to express p53, a tumor suppressor protein, and then vaccinated in mice. To enhance the effect, an oncolytic virus was introduced to promote the release of tumor antigens and stimulate the immune system. The study found that the combination of p53-transduced DCs and oncolytic virus led to a stronger antitumor immune response, resulting in improved tumor control and survival rates in preclinical models. This suggests a potential therapeutic strategy for enhancing cancer immunotherapy by combining p53 activation within DCs with oncolytic virus-mediated tumor lysis and immune stimulation.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!